Drugs / 40 Kd Pegylated interferon alfa 2a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02087111 Background | Apr 2014 → Nov 2016 | hepatitis C virus infection | Queen Mary University of London | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 40 Kd Pegylated interferon alfa 2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02087111 ↗ |
| Route | Subcutaneous | “180 µg in pre-filled syringe for sub-cutaneous injection” NCT02087111 ↗ |